RECURSION PHARMACEUTICALS

Recursion CFO’s insider sell‑off reveals cautious confidence: 5,396 shares at $3.41 amid a 35% yearly decline, signaling possible liquidity needs and bearish sentiment.

Recursion CEO Khan Najat sold 22,408 shares at $3.52, showing a planned, modest unloading that signals confidence in the AI‑drug pipeline rather than distress.

Recursion’s CFO’s steady insider sales show disciplined cash‑flow management, not a red flag—investors should watch clinical milestones, not panic.

Explore how Borgeson Blake’s July 7 2026 sale of 40,000 Recursion Pharma shares reveals insider strategy, market sentiment, and AI‑driven drug‑discovery prospects.

Insider buy by Recursion board member Dar Zavain signals confidence in the AI‑drug platform; watch for pipeline milestones that could lift the stock.